· Regulation · Regulation Desk
With injectable semaglutide and tirzepatide off the active shortage list, the 503A/503B compounding window is closing. What changes now, enforcement timelines, and the legal status of compounded GLP-1s under the post-shortage framework.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.